Literature DB >> 18094333

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

Claire M Edwards1, James R Edwards, Seint T Lwin, Javier Esparza, Babatunde O Oyajobi, Brandon McCluskey, Steven Munoz, Barry Grubbs, Gregory R Mundy.   

Abstract

There is increasing evidence to suggest that the Wnt signaling pathway plays a critical role in the pathogenesis of myeloma bone disease. In the present study, we determined whether increasing Wnt signaling within the bone marrow microenvironment in myeloma counteracts development of osteolytic bone disease. C57BL/KaLwRij mice were inoculated intravenously with murine 5TGM1 myeloma cells, resulting in tumor growth in bone and development of myeloma bone disease. Lithium chloride (LiCl) treatment activated Wnt signaling in osteoblasts, inhibited myeloma bone disease, and decreased tumor burden in bone, but increased tumor growth when 5TGM1 cells were inoculated subcutaneously. Abrogation of beta-catenin activity and disruption of Wnt signaling in 5TGM1 cells by stable overexpression of a dominant-negative TCF4 prevented the LiCl-induced increase in subcutaneous growth but had no effect on LiCl-induced reduction in tumor burden within bone or on osteolysis in myeloma-bearing mice. Together, these data highlight the importance of the local microenvironment in the effect of Wnt signaling on the development of myeloma bone disease and demonstrate that, despite a direct effect to increase tumor growth at extraosseous sites, increasing Wnt signaling in the bone marrow microenvironment can prevent the development of myeloma bone disease and inhibit myeloma growth within bone in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094333      PMCID: PMC2254537          DOI: 10.1182/blood-2007-03-077685

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Authors:  Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

2.  Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice.

Authors:  Philippe Clément-Lacroix; Minrong Ai; Frederic Morvan; Sergio Roman-Roman; Béatrice Vayssière; Cecille Belleville; Kenneth Estrera; Matthew L Warman; Roland Baron; Georges Rawadi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

3.  A murine model of human myeloma bone disease.

Authors:  I R Garrett; S Dallas; J Radl; G R Mundy
Journal:  Bone       Date:  1997-06       Impact factor: 4.398

4.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells.

Authors:  O Tetsu; F McCormick
Journal:  Nature       Date:  1999-04-01       Impact factor: 49.962

5.  Wnts induce migration and invasion of myeloma plasma cells.

Authors:  Ya-Wei Qiang; Katie Walsh; Lei Yao; Noemi Kedei; Peter M Blumberg; Jeffrey S Rubin; John Shaughnessy; Stuart Rudikoff
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

6.  Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease.

Authors:  S L Dallas; I R Garrett; B O Oyajobi; M R Dallas; B F Boyce; F Bauss; J Radl; G R Mundy
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

Review 7.  Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.

Authors:  Madhusmita Misra; George I Papakostas; Anne Klibanski
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

8.  Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

Authors:  Takashi Oshima; Masahiro Abe; Jin Asano; Tomoko Hara; Kenichi Kitazoe; Etsuko Sekimoto; Yoichi Tanaka; Hironobu Shibata; Toshihiro Hashimoto; Shuji Ozaki; Shinsuke Kido; Daisuke Inoue; Toshio Matsumoto
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

9.  Lithium carbonate therapy is not a risk factor for osteoporosis.

Authors:  O Cohen; T Rais; E Lepkifker; I Vered
Journal:  Horm Metab Res       Date:  1998-09       Impact factor: 2.936

10.  Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.

Authors:  Gary J Spencer; Jennifer C Utting; Sharon L Etheridge; Timothy R Arnett; Paul G Genever
Journal:  J Cell Sci       Date:  2006-03-07       Impact factor: 5.285

View more
  76 in total

Review 1.  Update in new anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis
Journal:  J Clin Endocrinol Metab       Date:  2010-04       Impact factor: 5.958

Review 2.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

Review 3.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

4.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 5.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 6.  Metastasis and bone loss: advancing treatment and prevention.

Authors:  Robert E Coleman; Allan Lipton; G David Roodman; Theresa A Guise; Brendon F Boyce; Adam M Brufsky; Philippe Clézardin; Peter I Croucher; Julie R Gralow; Peyman Hadji; Ingunn Holen; Gregory R Mundy; Matthew R Smith; Larry J Suva
Journal:  Cancer Treat Rev       Date:  2010-05-15       Impact factor: 12.111

Review 7.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

8.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

9.  Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.

Authors:  Claire M Edwards; Seint T Lwin; Jessica A Fowler; Babatunde O Oyajobi; Junling Zhuang; Andreia L Bates; Gregory R Mundy
Journal:  Am J Hematol       Date:  2009-05       Impact factor: 10.047

10.  A murine model of myeloma that allows genetic manipulation of the host microenvironment.

Authors:  Jessica A Fowler; Gregory R Mundy; Seint T Lwin; Conor C Lynch; Claire M Edwards
Journal:  Dis Model Mech       Date:  2009-09-24       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.